drugset
drugset / Trial / NCT03303066

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

NCT03303066 ↗

Phase 2/3 Completed 43 enrolled Kyntra Bio AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study to evaluate the efficacy FG-4592 for the treatment of anemia in Chinese participants with lower risk MDS.

Timeline

Start
2018-06-06
Primary completion
2023-01-11
Completion
2023-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Roxadustat Small molecule — Oral

Indications

anemia myelodysplastic syndrome